(function(){
			var content_array=["<p><b>关于龙沙（<\/b><b>&nbsp;Lonza<\/b><b>）<\/b><\/p> \n<p>龙沙是全球制药、生物技术与营养市场的优秀合作伙伴。&nbsp;我们致力于疾病预防，并通过助力客户推出创新药物辅助治疗一系列的疾病，促进世界更健康。我们将先进生产制造、科学专业技术、卓越工艺与技术洞察力完美结合以达成目标，帮助客户在医疗健康领域的发现与创新成果实现商业化。<\/p> \n<p>1897年，龙沙诞生于瑞士的阿尔卑斯山脉地区。发展至今，业务已遍及全球五大洲。我们拥有约14,000名全职员工，由他们组成的高效团队及每一名员工都为我们的业务和所在地区及国家做出意义非凡的改变。2020年，公司销售额达45亿瑞士法郎，核心业务的息税折旧摊销前利润（EBITDA）达14亿瑞士法郎。更多详情，请访问&nbsp;<a target=\"_blank\" href=\"https:\/\/t.prnasia.com\/t\/Uzp6Qwss\" rel=\"nofollow\">www.lonza.com<\/a>。<\/p> \n<p><b>关于<\/b><b>Pinteon Therapeutics<\/b><\/p> \n<p>Pinteon Therapeutics正在推进一种新型抗体的临床研究，旨在中断毒性Tau的传播，保护并保留神经退行性病患的脑部功能。Pinteon主打的PNT001是目前在研项目中<span id=\"spanHghlt1a4a\">唯一一款<\/span>靶向cis-pT231 Tau的抗体。cis-pT231 Tau是一种神经毒性表位，已在多项临床前研究中被证实是引发神经退行性疾病的主要驱动因素之一。Pinteon由Morningside Ventures提供资金支持，拥有一支经验丰富的管理团队，并在CNS药物发现和开发方面拥有优秀的记录。欲了解更多信息，请访问<a target=\"_blank\" href=\"https:\/\/t.prnasia.com\/t\/NUm0OZmV\" rel=\"nofollow\">pinteon.com<\/a><\/p> \n<p><b><span id=\"spanHghltc46c\">Lonza Contact Details <br \/><\/span><\/b><\/p> \n<p><span id=\"spanHghlt3ccc\"><b><span class=\"xn-person\">Victoria Morgan<\/span> <br \/><\/b>Head of External Communications <br \/>Lonza Group Ltd <br \/>Tel +41 61 316 2283 <br \/><\/span><a target=\"_blank\" href=\"https:\/\/t.prnasia.com\/t\/o3N4JP7J\" rel=\"nofollow\"><span id=\"spanHghlt7536\">victoria.morgan@lonza.com<\/span><\/a><\/p> \n<p><span id=\"spanHghltd7c4\"><b>Dr. Martina Ribar Hestericov&aacute; <br \/><\/b>Trade Media Lead <br \/>Lonza Group Ltd <br \/>Tel +41 61 316 8982 <br \/><\/span><a target=\"_blank\" href=\"https:\/\/t.prnasia.com\/t\/Kh5tDlGH\" rel=\"nofollow\"><span id=\"spanHghlt3c63\">martina.ribarhestericova@lonza.com<\/span><\/a><\/p> \n<p><span id=\"spanHghlt1c5a\"><b><span class=\"xn-person\">Dirk Oehlers<\/span> <br \/><\/b>Investor Relations <br \/>Lonza Group Ltd <br \/>Tel +41 61 316 8540 <br \/><\/span><a target=\"_blank\" href=\"https:\/\/t.prnasia.com\/t\/ox4DUVEv\" rel=\"nofollow\"><span id=\"spanHghlt43df\">dirk.oehlers@lonza.com<\/span><\/a><\/p> \n<p><b><span id=\"spanHghltea0d\">Pinteon Therapeutics Contact Details <\/span><\/b><\/p> \n<p><span id=\"spanHghlt4b4c\"><b><span class=\"xn-person\">Lisa Qu<\/span><\/b> <br \/>Media contact <br \/>Ten Bridge Communications <br \/>Tel +1 678-662-9166 <br \/><\/span><a target=\"_blank\" href=\"https:\/\/t.prnasia.com\/t\/smHnvqys\" rel=\"nofollow\"><span id=\"spanHghlt49d0\">lqu@tenbridgecommunications.com<\/span><\/a>&nbsp;<\/p> \n<p><b>Additional Information and Disclaimer<\/b><\/p> \n<p>Lonza Group Ltd has its headquarters in <span class=\"xn-location\">Basel, Switzerland<\/span>, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (&quot;SGX-ST&quot;). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.<\/p> \n<p>Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.<\/p> \n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"> \n<\/div>"];
			$("#dvExtra").html(content_array[0]);})();